Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Female Sexual Arousal Disorder Clear all
Completed Phase 2 Interventional Results available

Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder

NCT01382719
View directory record Official record
Conditions
Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder
Interventions
bremelanotide
Drug
Lead sponsor
Palatin Technologies, Inc
Industry
Eligibility
21 Years and older · Female only
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
65
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Not applicable Interventional Results available

A Mindfulness-based Intervention for Older Women With Low Sexual Desire

NCT03232801
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder, Sexual Dysfunction, Female Sexual Dysfunction
Interventions
mindfulness-based multicomponent intervention, general health education group
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
50 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Jul 22, 2026, 5:07 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause

NCT07408440
View directory record Official record
Conditions
Menopause, Sexual Dysfunction, Libido Disorder, Testosterone Deficiency
Interventions
Transdermal testosterone gel, Transdermal placebo gel
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Phase 2 Interventional

An Open-Label, Extension Study Evaluating the Safety, Toleration, and Efficacy of Sildenafil in Women With Sexual Arousal Disorder

NCT00746967
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological, Sexual Arousal Disorder
Interventions
sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
82
States / cities
Huntsville, Alabama • Anchorage, Alaska • Tucson, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Not applicable Interventional

Heart Rate Variability Biofeedback for Female Sexual Arousal Disorder

NCT02958176
View directory record Official record
Conditions
Female Sexual Arousal Disorder
Interventions
HRV Biofeedback, Autogenic Training
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Not applicable Interventional

Viveve Geneveve Treatment of the Vaginal Introitus to Evaluate Safety and Efficacy

NCT03479229
View directory record Official record
Conditions
Female Sexual Dysfunction
Interventions
Geneveve Treatment, Sham Treatment
Device
Lead sponsor
Viveve Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
19
States / cities
La Mesa, California • Orange, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Phase 2 Interventional Results available

Estetrol for the Treatment of Female Sexual Arousal Disorder in Postmenopausal Women

NCT06308614
View directory record Official record
Conditions
Sexual Dysfunction, Physiological
Interventions
Estetrol, Placebo
Drug · Other
Lead sponsor
Estetra
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
24
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Phase 3 Interventional

Zestra in Women With Mixed Sexual Dysfunction

NCT00118495
View directory record Official record
Conditions
Sexual Dysfunction, Psychological
Interventions
Non-prescription Zestra(TM): patented formulation
Drug
Lead sponsor
QualiLife Pharmaceuticals
Industry
Eligibility
21 Years to 65 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
13
States / cities
Tarzana, California • Aurora, Colorado • Aventura, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2007 · Synced Jul 22, 2026, 5:07 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Alprostadil (FemLife Gel) in the Treatment of Female Sexual Arousal Disorder

NCT00572377
View directory record Official record
Conditions
Female Sexual Arousal Disorder
Interventions
FemLife Gel, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2008 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Phase 2 Interventional

Study to Investigate Effect of Sildenafil on Clitoral Engorgement as Measured by Magnetic Resonance Imaging (MRI) in Pre-menopausal Women With Female Sexual Arousal Disorder

NCT00640458
View directory record Official record
Conditions
Female Sexual Arousal Disorder
Interventions
Sildenafil 100 mg, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Phase 2 Interventional

Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction

NCT00034021
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder, Sexual Dysfunctions, Psychological
Interventions
Ginkgo Biloba, Sex Therapy (genital focus)
Drug · Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2006 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of SST-6007, a Topical Sildenafil Cream, Compared to Placebo in Women With Female Sexual Arousal Disorder

NCT02570282
View directory record Official record
Conditions
Sexual Arousal Disorder
Interventions
Placebo, SST-6007
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
21 Years to 60 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Not applicable Interventional

Efficacy of Exercise for Sexual Side Effects of Antidepressants

NCT01189825
View directory record Official record
Conditions
Sexual Dysfunction
Interventions
Exercise
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Phase 2 Interventional

Topical Alprostadil for Female Sexual Arousal Disorder

NCT00324948
View directory record Official record
Conditions
Sexual Dysfunction, Physiological
Interventions
Topical alprostadil (PGE-1)
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
21 Years to 60 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Stanford, California • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2009 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Phase 1 Interventional

Examining Caffeine as a Treatment for Antidepressant-induced Arousal Dysfunction in Women

NCT05685407
View directory record Official record
Conditions
Female Sexual Arousal Disorder
Interventions
Caffeine, Placebo
Drug · Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Not applicable Interventional

A Study Evaluating the Effects of Topical Clitoral Estradiol Cream in Post Menopausal Women

NCT02859285
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Placebo vulvar cream, Estradiol vulvar cream
Other
Lead sponsor
ProHealth Care, Inc
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Waukesha, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Surface Stimulation for Female Sexual Dysfunction

NCT02692417
View directory record Official record
Conditions
Female Sexual Dysfunction
Interventions
Transcutaneous Electrical Nerve Stimulation
Device
Lead sponsor
Timothy Bruns
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Jul 22, 2026, 5:07 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Sexual Penetration Pain in Postmenopausal Women: A Topical Botanical Drug Treatment

NCT03682601
View directory record Official record
Conditions
Sexual Pain Disorders, Postmenopausal Symptoms, Vulvovaginal Atrophy, Female Sexual Dysfunction, Dyspareunia, Vulvodynia, Vestibulodynia, Arousal Disorders, Sexual, Genito-Pelvic Pain/Penetration Disorder, Female Sexual Arousal Disorder
Interventions
5% sinecatechins ointment, Placebo, 10% sinecatechins ointment
Drug
Lead sponsor
GTO Pharmaceutical, LLC
Other
Eligibility
20 Years to 70 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
4
States / cities
New York, New York • Nyack, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Jul 22, 2026, 5:07 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder

NCT04948151
View directory record Official record
Conditions
Female Sexual Arousal Disorder
Interventions
Sildenafil, Placebo
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
21 Years and older · Female only
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
51
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Phase 2 Interventional

Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)

NCT00425256
View directory record Official record
Conditions
Sexual Arousal Disorder
Interventions
Bremelanotide
Drug
Lead sponsor
Palatin Technologies, Inc
Industry
Eligibility
21 Years to 70 Years · Female only
Timeline
2006 – 2007
U.S. locations
20
States / cities
Huntsville, Alabama • Tucson, Arizona • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2011 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Early Abuse on Adult Intimate Relationships

NCT01803802
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder, Female Sexual Arousal Disorder, Female Orgasmic Disorder, Major Depressive Disorder, Post-traumatic Stress Disorder
Interventions
Expressive writing
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older · Female only
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1b/2a Unblinded Study of Responses in Premenopausal Women With HSDD to Lorexys Evaluating Efficacy and Safety

NCT01857596
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder (DSM-IV-TR Defined), Sexual Interest/Arousal Disorder (DSM-5 Defined)
Interventions
bupropion, Lorexys low-dose, Lorexys moderate-dose
Drug
Lead sponsor
S1 Biopharma, Inc.
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Beachwood, Ohio • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Jul 22, 2026, 5:07 PM EDT